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Background
The Cambodian National Influenza Center (NIC) was established in August 2006 for the purpose of documenting the dynamics of influenza disease and to virologically characterize the circulating strains. To continuously monitor influenza activity, a hospital-based sentinel surveillance system for ILI (influenza-like illness) with a weekly reporting and sampling scheme was initially established in five sites in 2006. In addition, hospitalbased surveillance of acute lower respiratory infection (ALRI) cases was established in 2 sites.
Methods
The sentinel sites collected weekly epidemiological data from patients who fulfilled the ILI case definition, and took naso-pharyngeal specimens from 5 to 10 cases per week. Over 4100 respiratory samples were collected from hospitalized ALRI patients between 2007 and 2010. All samples were tested in the Virology Unit at the Institut Pasteur in Phnom Penh. Viral RNA was extracted and amplified by a multiplex RT-PCR detecting influenza A and influenza B virus simultaneously. Influenza A viruses were then subtyped and analyzed by hemagglutination inhibition assay. The susceptibility to neuraminidase inhibitor drugs (oseltamivir, and zanamivir) was determined using the NA-STAR kit (Applied Biosystems®). Genetic analyses targeting HA, NA, and M genes were conducted on strains selected randomly.
Results
We observed that 5.8% ( Peak seasonal influenza activity in Cambodia occurred during the rainy season from August to November. Although Cambodia is a tropical country geographically located in the northern hemisphere, influenza activity has a southern hemisphere transmission pattern. Therefore, while the northern hemisphere vaccine may provide partial protection in Cambodia, the southern hemisphere vaccine is recommended. The drug susceptibility profile of Cambodian influenza strains revealed that neuraminidase inhibitors would be the drug of choice for influenza treatment and chemoprophylaxis in Cambodia, as adamantanes are no longer expected to be effective. 
